Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic photodynamic therapy for organ transplant patients
2008-006863-35Phase 4Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jul 2013
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methyl aminolevulinate in actinic keratosis (AK), non-melanoma skin cancer (NMSC) and Wart (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Number of newly developed AK or skin cancer in the treatment areas. Started Jul 2013; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)non-melanoma skin cancer (NMSC)Wart
Beyond the preview
Go deeper on 2008-006863-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006863-35.